Smith Group Asset Management
RGLS icon

Smith Group Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Smith Group Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-952
Closed -$1.08M – 433
2013
Q3 		$1.08M Buy
+952
New +$1.12M 0.04% 175

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HealthCor Management
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smith Group Asset Management's RGLS Position: Q4 2013 in Review

Smith Group Asset Management sold out of Regulus Therapeutics (RGLS) in Q4 2013, closing a stake of 952 shares — an estimated $1.08M sold.

Smith Group Asset Management first reported a position in RGLS in Q3 2013 and held it in 1 quarter. The position peaked at $1.08M in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q4 2013.

  • Smith Group Asset Management reported no remaining Regulus Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Smith Group Asset Management sold 952 Regulus Therapeutics shares in Q4 2013, an estimated $1.08M.
  • Smith Group Asset Management first reported a position in Regulus Therapeutics in Q3 2013 and held it in 1 quarter.
  • Smith Group Asset Management's Regulus Therapeutics position peaked at $1.08M in Q3 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2013.

Based on Smith Group Asset Management's 13F filing for Q4 2013, filed 29 Jan 2014.